Extavia (IFN-β-1b) / Novartis  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Extavia (IFN-β-1b) / Novartis
NCT02749396: EPID Multiple Sclerosis Pregnancy Study

Completed
N/A
2089
Europe
Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG, Extavia (interferon beta-1b), Novartis Pharma AG, Rebif (interferon beta-1a), Merck Serono Europe Ltd, Plegridy (peginterferon beta-1a), Biogen Idec Ltd, Avonex (interferon beta-1a), Biogen Idec Ltd, MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046), No MSDMDs therapy (control)
Bayer, EPID Research, Biogen, Merck Serono Europe Ltd, Novartis Pharmaceuticals
Multiple Sclerosis
08/18
08/18
PERFECT, NCT03347370: A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis

Completed
N/A
626
Europe
SC Peginterferon beta-1a, Plegridy, SC interferon beta-1a, Rebif, SC interferon beta-1b, Betaferon, Extavia
Biogen, AMS Advanced Medical Services GmbH
Multiple Sclerosis, Relapsing-Remitting
07/19
07/19
INFORM, NCT06053749: An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden

Not yet recruiting
N/A
100
Europe
Avonex (IFNβ-1-a, Biogen Netherlands B.V), Rebif (IFNβ-1-a, Merck Europe B.V.), Extavia (IFNβ-1-b, Novartis Europharm Limited), Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG), Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V), MS disease modifying drugs (MSDMDs)
Bayer, Biogen Netherlands B.V, Novartis Europharm Limited, Merck Europe B.V.
Multiple Sclerosis (MS)
03/26
03/26

Download Options